NEW YORK (GenomeWeb) – Genomeon and Cloud Pharmaceuticals have signed an agreement to mine next-generation sequencing data to aid in drug development.

Under the terms of the agreement, Cloud Pharmaceuticals will be able to use Genomeon's microsatellite technology to find novel drug targets and companion biomarkers in NGS data.

Floyd, Virginia-based Genomeon analyzes short tandem repeat sequences, called microsatellites, which could serve as drug targets or biomarkers for diagnostic purposes.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

The New York Times and ProPublica look into the close relationship between a startup and Memorial Sloan Kettering Cancer Center.

Yahoo News reports millions of dollars are being transferred from NIH, CDC, and other programs to pay for the housing of detained undocumented immigrant children.

In Science this week: in vitro generation of human reproductive cells, and more.

Researchers gave a handful of octopuses MDMA to find that they too act more social on the drug, Gizmodo reports.